Myofibroma/myofibromatosis: a clinicopathologic analysis of 9 cases
10.3760/cma.j.issn.0529-5807.2018.01.009
- VernacularTitle: 肌纤维瘤/肌纤维瘤病九例临床病理学分析
- Author:
Yao FU
1
;
Wenyan GUAN
;
Haiyan WU
;
Hongyan WU
;
Zhiwen FAN
;
Qing YE
;
Fanqing MENG
Author Information
1. Department of Pathology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China
- Publication Type:Journal Article
- Keywords:
Myofibroma;
Myofibromatosis;
Receptor, platelet-derived growth factor beta;
In situ hybridization, fluorescence
- From:
Chinese Journal of Pathology
2018;47(1):45-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical and histological features, diagnosis and differential diagnosis of myofibroma/myofibromatosis.
Methods:The clinical data and pathology features of nine cases of myofibroma/myofibromatosis were collected from August 2011 to November 2016 in Affiliated Drum Tower Hospital, Nanjing University Medical School and Children′s Hospital of Nanjing Medical University. Immunohistochemistry(IHC), PDGFRB molecular analysis and ETV6-NTRK3 gene fusion were performed and relevant literature reviewed.
Results:There were 7 males and 2 females, with age ranging from 3 days to 18 years (mean 5 years). The tumors were located in head and neck (eight cases) and trunk (one case). Clinically, the tumors presented as freely movable nodules. Microscopically, they appeared biphasic with alternating light- and dark-staining areas. The light-staining area consisted mainly of plump myoid spindle cells with eosinophilic cytoplasm arranged in nodules, short fascicles, or whorls.The dark-staining area was composed of round or polygonal cells with slightly hyperchromatic nuclei or small spindle cells arranged around a distinct hemangiopericytoma-like vascular pattern. IHC showed the tumor cells in the light-staining area were strongly positive for vimentin and SMA, while cells in dark-staining area were strongly positive for vimentin, and weakly for SMA. Tumor cells were negative for desmin, S-100 protein, h-Caldesmon, CD34 and STAT6. Analysis of PDGFRB mutations was performed in seven cases. Two cases showed 12 exon point mutation c. 1681 c>T(p.R561C), one case showed 14 exon point mutation c. 1998C>G (p.N666K). ETV6-NTRK3 gene fusion was not detected by fluorescence in situ hybridization in four patients under three years old. All cases were followed for 6 to 68 months, with two recurrences.
Conclusions:Myofibroma/myofibromatosis is an uncommon benign myofibroblastic tumor of infancy and childhood. The tumor can appear biphasic, and may show PDGFRB point mutation which is of potential diagnostic value.
